IXICO plc Statement re Annual Report and Notice of AGM (5652X)
20 Diciembre 2019 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 5652X
IXICO plc
20 December 2019
20 December 2019
IXICO plc
("IXICO" or the "Company")
Posting of Annual Report and Notice of AGM
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, confirms that the Annual Report and
Accounts for the year ended 30 September 2019 ("Annual Report and
Accounts 2019") and the Notice of Annual General Meeting ("AGM")
have been posted to shareholders on 12 December and 16 December,
respectively. A copy of the 2019 Annual Report and Accounts is
available to download from the Company website on
www.IXICO.com.
The AGM will be held at BGF Investment Management, 13-15 York
Buildings, London, WC2N 6JU on 17 January 2020 at 10.30 a.m.
For further information please contact:
IXICO plc +44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0) 20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Optimum Strategic Communications +44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Manel Mateus
IXICO@optimumcomms.com
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of Artificial
Intelligence (AI) in clinical development, to improve biopharma
R&D productivity through the adoption of breakthrough data
analytics in precision healthcare. Through the deployment of novel
AI algorithms, we analyse and interpret brain scans and digital
biosensor data to enable better trial design, patient selection and
ultimately clinical outcomes across all phases of clinical
evaluation. Our data analytics services are deployed on some of the
most important clinical trials in neuroscience, providing valuable
insights to disease progression and patient safety, enabling our
clients to make better informed decisions earlier in the clinical
development pathway.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRFFFFAUFUSELE
(END) Dow Jones Newswires
December 20, 2019 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024